Table 5.
Impact of marker status on clinical and pathological tumor features in TACE treated HCC
| |
EpCAM |
|
CD133 |
|
||
|---|---|---|---|---|---|---|
| Low (n = 6) | High (n = 10) | P | Low (n = 4) | High (n = 12) | P | |
|
Age (year) |
58(53–65) |
56(48–68) |
0.236 |
52(48–57) |
58(49–68) |
0.070 |
|
Gender (F/M) |
1/5 |
1/9 |
0.696 |
0/4 |
2/12 |
0.383 |
|
AFP (ng/ml) |
1333(4–7254) |
256(3–2000) |
0.289 |
297(8–43) |
870(3–7254) |
0.177 |
|
Interval between |
189(82–345) |
224(73–337) |
0.479 |
260(188–327) |
194(73–377) |
0.217 |
|
TACE and Tx (days) |
|
|
|
|
|
|
|
More than one TACE |
1/6 |
3/10 |
0.639 |
2/4 |
2/12 |
0.329 |
|
Tumor Size (mm) |
45(25–76) |
34(20–55) |
0.181 |
36(32–40) |
39(20–76) |
0.744 |
|
Tumor differentiation |
|
|
0.024 |
|
|
0.834 |
| Well |
0 |
1 |
|
0 |
1 |
|
| Moderately |
6 |
3 |
|
3 |
8 |
|
| Poor |
0 |
6 |
|
1 |
3 |
|
|
TNM Stages |
|
|
0.302 |
|
|
0.248 |
| I |
4 |
4 |
|
1 |
7 |
|
| II | 2 | 6 | 3 | 5 | ||